Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Leport

Showing results (211-220 of 235) with videos related to

Pageof 24
Sort By:
Clinical and Diagnostic Laboratory Immunology|May 1, 2001
Immunoblot profile as predictor of toxoplasmic encephalitis in patients infected with human immunodeficiency virusC Leport, J Franck, G Chene, et al.
Annales De Medecine Interne|January 1, 1989
[AIDS in elderly patients. Apropos of 22 cases observed in the Paris region]Q Nguyen, M Laurent, J P Bouchon, et al.
Medecine Et Maladies Infectieuses|November 25, 2017
The French Infectious Diseases Society's readiness and response to epidemic or biological risk-the current situation following the Middle East respiratory syndrome coronavirus and Ebola virus disease alertsH Coignard-Biehler, C Rapp, J M Chapplain, et al.
The American Journal of Clinical Nutrition|February 1, 1991
Resting energy expenditure is increased in stable, malnourished HIV-infected patientsJ C Melchior, D Salmon, D Rigaud, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|July 27, 2001
Clinical, biologic, and behavioral predictors of early immunologic and virologic response in HIV-infected patients initiating protease inhibitorsV Le Moing, G Chêne, M P Carrieri, et al.
HIV Medicine|January 7, 2010
Is long-term virological response related to CCR5 Delta32 deletion in HIV-1-infected patients started on highly active antiretroviral therapy?J-J Laurichesse, A Taieb, C Capoulade-Metay, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 1, 1997
Increased risk of toxoplasmic encephalitis in human immunodeficiency virus-infected patients with pyrimethamine-related rash. ANRS 005-ACTG 154 Trial Group. Agence Nationale de Recherche sur le SIDA (ANRS-INSERM) and the NIAID-AIDS Clinical Trials GroupF Rousseau, S Pueyo, P Morlat, et al.
The Journal of Infectious Diseases|January 1, 1996
Pyrimethamine for primary prophylaxis of toxoplasmic encephalitis in patients with human immunodeficiency virus infection: a double-blind, randomized trial. ANRS 005-ACTG 154 Group Members. Agence Nationale de Recherche sur le SIDA. AIDS Clinical Trial GroupC Leport, G Chêne, P Morlat, et al.
Controlled Clinical Trials|June 10, 1998
Intention-to-treat vs. on-treatment analyses of clinical trial data: experience from a study of pyrimethamine in the primary prophylaxis of toxoplasmosis in HIV-infected patients. ANRS 005/ACTG 154 Trial GroupG Chêne, P Morlat, C Leport, et al.
The New England Journal of Medicine|September 30, 1993
Toxoplasmic encephalitis in patients with the acquired immunodeficiency syndrome. Members of the ACTG 077p/ANRS 009 Study TeamB J Luft, R Hafner, A H Korzun, et al.
Pageof 24

Showing results (211-220 of 235) with videos related to

Sort By:
Pageof 24
Clinical and Diagnostic Laboratory Immunology|May 1, 2001
Immunoblot profile as predictor of toxoplasmic encephalitis in patients infected with human immunodeficiency virusC Leport, J Franck, G Chene, et al.
Annales De Medecine Interne|January 1, 1989
[AIDS in elderly patients. Apropos of 22 cases observed in the Paris region]Q Nguyen, M Laurent, J P Bouchon, et al.
Medecine Et Maladies Infectieuses|November 25, 2017
The French Infectious Diseases Society's readiness and response to epidemic or biological risk-the current situation following the Middle East respiratory syndrome coronavirus and Ebola virus disease alertsH Coignard-Biehler, C Rapp, J M Chapplain, et al.
The American Journal of Clinical Nutrition|February 1, 1991
Resting energy expenditure is increased in stable, malnourished HIV-infected patientsJ C Melchior, D Salmon, D Rigaud, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|July 27, 2001
Clinical, biologic, and behavioral predictors of early immunologic and virologic response in HIV-infected patients initiating protease inhibitorsV Le Moing, G Chêne, M P Carrieri, et al.
HIV Medicine|January 7, 2010
Is long-term virological response related to CCR5 Delta32 deletion in HIV-1-infected patients started on highly active antiretroviral therapy?J-J Laurichesse, A Taieb, C Capoulade-Metay, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 1, 1997
Increased risk of toxoplasmic encephalitis in human immunodeficiency virus-infected patients with pyrimethamine-related rash. ANRS 005-ACTG 154 Trial Group. Agence Nationale de Recherche sur le SIDA (ANRS-INSERM) and the NIAID-AIDS Clinical Trials GroupF Rousseau, S Pueyo, P Morlat, et al.
The Journal of Infectious Diseases|January 1, 1996
Pyrimethamine for primary prophylaxis of toxoplasmic encephalitis in patients with human immunodeficiency virus infection: a double-blind, randomized trial. ANRS 005-ACTG 154 Group Members. Agence Nationale de Recherche sur le SIDA. AIDS Clinical Trial GroupC Leport, G Chêne, P Morlat, et al.
Controlled Clinical Trials|June 10, 1998
Intention-to-treat vs. on-treatment analyses of clinical trial data: experience from a study of pyrimethamine in the primary prophylaxis of toxoplasmosis in HIV-infected patients. ANRS 005/ACTG 154 Trial GroupG Chêne, P Morlat, C Leport, et al.
The New England Journal of Medicine|September 30, 1993
Toxoplasmic encephalitis in patients with the acquired immunodeficiency syndrome. Members of the ACTG 077p/ANRS 009 Study TeamB J Luft, R Hafner, A H Korzun, et al.
Pageof 24